Yi-Xiang Zhu (Yixiang Zhu)

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 10

Top Topics

Metastatic Colorectal Cancer

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Cancer medicine

Evidence-based complementary and alternative medicine : eCAM

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Li, Ziyi Xu, Shou-Zheng Wang, Yi-Xiang Zhu, Di Ma, Yuxin Mu, Jian-Ming Ying, Jun-Ling Li, Pu-Yuan Xing
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic cancer 13 (15) (2022)
Geyun Chang, Weihua Li, Hua Bai, Jianchun Daun, Zhijie Wang, Xinyang Du, Ruofei Yu, Yaxi Wang, Minghao Wang, Yi-Xiang Zhu, Xue Zhang, Li Li, Rui Wan, Jie Wang
Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 13 (21) (2022)
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yi-Xiang Zhu, Jie Wang
Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs. Thoracic cancer 13 (9) (2022)
Tongji Xie, Zihua Zou, Chengcheng Liu, Yi-Xiang Zhu, Ziyi Xu, Le Wang, Jun-Ling Li, Pu-Yuan Xing
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM 2021 (2021)
Yiying Guo, Lin Yang, Li Liu, Jiacong Wei, Fei Teng, Jinyao Zhang, Yi-Xiang Zhu, Puyuan Xing, Jun-Ling Li
Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. Thoracic cancer 11 (10) (2020)
Pu-Yuan Xing, Yi-Xiang Zhu, Le Wang, Zhou-Guang Hui, Shang-Mei Liu, Jian-Song Ren, Ye Zhang, Yan Song, Cheng-Cheng Liu, Yun-Chao Huang, Xian-Zhen Liao, Xiao-Jing Xing, De-Bin Wang, Li Yang, Ling-Bin Du, Yu-Qin Liu, Yong-Zhen Zhang, Yun-Yong Liu, Dong-Hua Wei, Kai Zhang, Ju-Fang Shi, You-Lin Qiao, Wan-Qing Chen, Jun-Ling Li, Min Dai, null null
What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer medicine 8 (8) (2019)
Lin Yang, Yiqun Che, Lei Guo, Bo Zheng, Bingning Wang, Zhenxi Yang, Yi-Xiang Zhu, Junling Li
Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China. Thoracic cancer 9 (4) (2018)
Puyuan Xing, Yuxin Mu, Yan Wang, Xuezhi Hao, Yi-Xiang Zhu, Xingsheng Hu, Hongyu Wang, Peng Liu, Lin Lin, Zhijie Wang, Junling Li
Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. Thoracic cancer 9 (12) (2018)
Puyuan Xing, Yuxin Mu, Yan Wang, Xuezhi Hao, Yi-Xiang Zhu, Xingsheng Hu, Hongyu Wang, Peng Liu, Lin Lin, Zhijie Wang, Junling Li
Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. Thoracic cancer 9 (7) (2018)
Yi-Xiang Zhu, Puyuan Xing, Shouzheng Wang, Di Ma, Yuxin Mu, Xue Li, Ziyi Xu, Junling Li
Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma. Thoracic cancer 9 (3) (2018)